UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
Products Bimzelx Cimzia KYGEVVI Neupro Vimpat Briviact Fintepla Nayzilam Rystiggo ZILBRYSQ Keppra® (levetiracetam) injectionFull Prescribing Information and Medication Guide Keppra® (levetiracetam) tablets and oral solutionFull Prescribing Information and Medication Guide Keppra XR® (levetiracetam)Full Prescribing Information and Medication Guide Briviact®, Cimzia®, FINTEPLA®, Keppra XR®, Keppra®, Nayzilam®, Neupro® , RYSTIGGO® and ZILBRYSQ® are registered trademarks of the UCB Group of Companies. Vimpat® is a registered trademark used under license from Harris FRC Corporation. CONTACT UCBCARES INFO FOR HCPS REPORT ADVERSE EVENT
